title: The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis.
abstract: OBJECTIVE
  The use of infliximab in severe ulcerative colitis (UC) is established; however, its role in severe acute UC requires clarification. The present multicentre case series evaluated infliximab in hospitalized patients with steroid-refractory severe UC.
  
  
  METHODS
  Patients from six hospitals were retrospectively evaluated. Data collection included demographics, duration of disease and previous treatments. The primary end point was response to in-hospital infliximab; defined as discharge without colectomy.
  
  
  RESULTS
  Twenty-one patients (median age 26 years) were admitted between May 2006 and May 2008 with severe UC requiring intravenous steroids and given infliximab (median time to infusion eight days). Sixteen (76%) patients were discharged home without colectomy; three of these underwent colectomy at a later date. Of the remaining 13 patients (62%), all but two did not require further courses of steroids; six patients had infliximab as a bridge to azathioprine and seven patients were maintained on regular infliximab. Five patients required in-hospital colectomy after the initial infliximab.
  
  
  CONCLUSIONS
  In this real-life experience of infliximab in patients with steroid-refractory severe UC, infliximab appears to be a viable rescue therapy. The majority of patients were discharged without surgery and 62% maintained response either as a bridge to azathioprine or maintenance infliximab.
authors.affiliation: Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, Canada. brian_bressler@hotmail.com
authors.forename: B
authors.initials: B
authors.lastname: Bressler
authors.forename: J K
authors.initials: JK
authors.lastname: Law
authors.forename: N
authors.initials: N
authors.lastname: Al Nahdi Sheraisher
authors.forename: K
authors.initials: K
authors.lastname: Atkinson
authors.forename: M F
authors.initials: MF
authors.lastname: Byrne
authors.forename: H V
authors.initials: HV
authors.lastname: Chung
authors.forename: M
authors.initials: M
authors.lastname: Fishman
authors.forename: N
authors.initials: N
authors.lastname: Partovi
authors.forename: D
authors.initials: D
authors.lastname: Pearson
authors.forename: R
authors.initials: R
authors.lastname: Penner
authors.forename: R A
authors.initials: RA
authors.lastname: Enns
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001955:British Columbia; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy*; D003113:Colonoscopy; D005260:Female; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab